Comparison of two laboratory assays for the investigation of fibrin gel porosity

Aleksandra Antovic; Gun Jörneskog; Håkan N. Wallen

doi:10.1160/TH07-06-0390

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2007; 98(06): 1386-1388
DOI: 10.1160/TH07-06-0390

Letters to the Editor

Schattauer GmbH

Comparison of two laboratory assays for the investigation of fibrin gel porosity

Authors

Aleksandra Antovic

¹Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden
Gun Jörneskog

¹Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden
Håkan N. Wallen

¹Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden

Abstract

Full Text

References

References
1 Blombäck B, Carlsson K, Fatah K. et al. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75: 521-538.
2 Blombäck B, Carlsson K, Hessel B. et al. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta 1989; 997: 96-110.
3 Fatah K, Hamsten A, Blombäck B. et al. Fibrin gel net work characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992; 68: 130-135.
4 Fatah K, Silveira A, Tornvall P. et al. Proneness to formation of tight and rigid fibrin gel structure in men with myocardial infarction at young age. Thromb Haemost 1996; 76: 535-540.
5 Jörneskog G, Egberg N, Fagrell B. et al. Altered properties of the fibrin gel structure in patients with IDDM. Diabetologia 1996; 39: 1519-1523.
6 Kalani M, Silveira A, Blomback M. et al. Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers. Thromb Res 2007; 120: 653-661.
7 Jörneskog G, Fatah K, Blombäck M. Fibrin gel structure in diabetic patients before and during treatment with acetylsalicylic acid – a pilot study. Fibrinolysis Proteol 1998; 12: 360-365.
8 Jörneskog G, Hansson LO, Wallen NH. et al. Increased plasma fibrin gel porosity in patients with Type I diabetes during continuous subcutaneous insulin infusion. J Thromb Haemost 2003; 1: 1195-1201.
9 He S, Cao H, Antovic A. et al. Modifications of flow measurement to assay fibrin gel permeability in association with thrombin generation potential and/or fibrinogen clotting property. Blood Coagul Fibrinolysis 2005; 16: 61-67.
10 Nair CH, Azhar A, Dhall DP. Studies on fibrin network structure in human plasma. Part One: Methods for clinical application. Thromb Res 1991; 64: 455-476.
11 Pieters M, Jerling JC, Weisel JW. Effect of freezedrying, freezing and frozen storage of blood plasma on fibrin network characteristics. Thromb Res 2002; 107: 263-269.
12 Mills JD, Ariens RA, Mansfield MW. et al. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 2002; 106: 1938-1942.
13 Sjoland JA. A new optimized method for the determination of fibrin clot permeability. Blood Coagul Fibrinolysis 2005; 16: 579-583.
14 Carr ME, Shen LL, Hermans J. Mass-length ratio of fibrin fibers from gel permeation and light scattering. Biopolymers 1977; 16: 1-15.
15 Fatah K, Beving H, Albåge A. et al. Acetylsalicylic acid may protect the patient by increasing fibrin gel porosity. Is withdrawing of treatment harmful to the patient? Eur Heart J 1996; 17: 1362-1366.
16 Williams S, Fatah K, Hjemdahl P. et al. Better increase in fibrin gel porosity by low dose than intermediate dose acetylsalicylic acid. Eur Heart J 1998; 19: 1666-1672.
17 Antovic A, Perneby C, Jacobsson Ekman GJ. et al. Marked increase of fibrin gel permeability with very low dose ASA treatment. A new argument to use low dose ASA treatment in the prevention of atherotrombotic disease? Thromb Res 2005; 116: 509-517.
18 He S, Ekman GJ, Hedner U. The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia. J Thromb Haemost 2005; 3: 272-279.